Abstract
On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a blood cancer that affects two to three people per 100,000, in record time — four months — on the basis of positive outcomes in early-phase trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
npj Breast Cancer Open Access 02 December 2023
-
Cooperative NF-κB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer
Breast Cancer Research Open Access 06 April 2023
-
Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology
Signal Transduction and Targeted Therapy Open Access 19 November 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801–847 (1996).
King, R. W., Deshaies, R. J., Peters, J. -M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652–1659 (1996).
Kisslev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 121, 1–20 (2001).
Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071–3076 (2001).
Barnes, P. J. & Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).
Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613–619 (2001).
Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333−338 (1998).
Anderson, P. G. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617 (2003).
FDA Drug Approvals List [online] (cited 13 May 2003) <http://www.fda.gov/cder/foi/label/2003/021602lbl.pdf> (2003).
Zangari, M. et al. Marked activity also in Del 13 multiple myeloma (MM) of PS-341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. Proc. Am. Soc. Hematol. A387 (2002).
Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, ValcadeTM) in combination with pegylated liposomal doxorubicin (DoxilTM) in patients with refractory hematological malignancies. Proc. Am. Soc. Hematol. A388 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paramore, A., Frantz, S. Bortezomib. Nat Rev Drug Discov 2, 611–612 (2003). https://doi.org/10.1038/nrd1159
Issue Date:
DOI: https://doi.org/10.1038/nrd1159
This article is cited by
-
Cooperative NF-κB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer
Breast Cancer Research (2023)
-
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
npj Breast Cancer (2023)
-
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
Clinical and Experimental Medicine (2023)
-
Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology
Signal Transduction and Targeted Therapy (2022)
-
Severe cellular stress drives apoptosis through a dual control mechanism independently of p53
Cell Death Discovery (2022)